Article Per Year (5 Year)
p-Index From 2020 - 2025
0.23
P-Index
This Author published in this journals
All Journal Eksakta : Berkala Ilmiah Bidang MIPA
Murti, Anissa Wari
Unknown Affiliation
Agriculture, Biological Sciences & Forestry Astronomy Biochemistry, Genetics & Molecular Biology Chemical Engineering, Chemistry & Bioengineering Chemistry Civil Engineering, Building, Construction & Architecture Computer Science & IT Energy Engineering Environmental Science Materials Science & Nanotechnology Mathematics Mechanical Engineering

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search
Journal : Eksakta : Berkala Ilmiah Bidang MIPA

 1 
Molecular Pathogenesis of Human Rhinovirus (HRV) Infection Murti, Anissa Wari; Andi Yasmon
EKSAKTA: Berkala Ilmiah Bidang MIPA Vol. 25 No. 04 (2024): Eksakta : Berkala Ilmiah Bidang MIPA (E-ISSN : 2549-7464)
Publisher : Faculty of Mathematics and Natural Sciences (FMIPA), Universitas Negeri Padang, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24036/eksakta/vol25-iss04/540

Abstract

Human Rhinovirus (HRV) is a RNA virus belonging to the Picornaviriade family that most often causes acute respiratory infections (ARI). This virus can cause dangerous infections in children, people with chronic respiratory disorders, and individuals with low immunity. This virus can infect newborns six to eight  times and adults two to four times per year. In addition, HRV is the main cause of pneumonia and bronchiolitis which can worsen the symptoms of cystic fibrosis asthma. This article also discusses the development of the HRV replication process that occurs in the respiratory tract epithelium which takes place in several stages, starting with virus attachment and ending with the release of new virions. We also analyze the stages of neutralizing antibodies (nAbs) to prevent HRV infection. Currently, there are not any authorized antiviral drugs or HRV vaccination because this virus has highly variable antigenic sites. To develop a vaccine that can protect against various HRV serotypes, a consensus sequence that combines several strains is needed.
Co-Authors Andi Yasmon